Paper | The study | Leukotriene receptor antagonist | Other drugs | |||||||
First author | Year | Type of study | Patients (of relevant age) | Patients administered the LTRA | Age of patients | Participant characteristics (as presented in study) | LTRA administered | Dose information given | Length of drug administration prior to ADR presentation | Additional drugs administered by patients |
Lenney 26 | 2013 | Randomised, double-blind, placebo controlled, parallel study | 63 | 21 | 6–14 years 11 months | 40 males, 23 females (whole study) | Montelukast | 5 mg/day | 0–48 weeks | Inhaled fluticasone propionate 100 µg two times per day. |
Ammari 29 | 2018 | Prospective cohort study | 56 | 56 | 2–17 years | Not specified | Montelukast | Not specified | 1–24 weeks | Inhaled steroids. |
Ghosh 27 | 2006 | Prospective cohort study | 50 | 50 | 3–11 years | 28 males, 22 females | Montelukast | 3–4 years 4 mg, >4 years 5 mg | Not specified | Salbutamol or terbutaline, used when needed. |
Kukreja 28 | 2004 | Prospective cohort study | 881 | 881 | 6–14 years | 573 males, 308 females | Montelukast | 5 mg/day | 0–30 days | Short acting inhaled beta-2-agonists, used ‘as needed’. |
Arnold 45 | 2020 | Retrospective cohort study | 312 | 312 | age 6 (5–8) years (median (IQR)) | 55% male, 45% female | Montelukast | (0.5–17.8 mg/kg/day) | Not specified | Not specified. |
Benard 46 | 2017 | Retrospective cohort study | 223 | 106 | 1–17 years | 66 male, 40 female (case). 66 Caucasian, 21 North African, 4 black, 3 Asian, 3 East Indian, 3 Hispanic, 6 inter-racial/other (case). | Montelukast | 2 unknown, 53 4 mg/day, 47 5 mg/day, 4 10 mg/day | Not specified | Not specified. |
Erdem 47 | 2015 | Retrospective cohort study | 1024 | 1024 | Not specified (‘children’) | Not specified | Not specified | Not specified | Not specified | Not specified. |
Glocker-Lauf 48 | 2018 | Matched, nested case–control study | 4395 | 4395 | 5–18 years | 1874/3497 female (control), 476/898 female (case). | Montelukast | Not specified | Not specified | ‘Asthma Maintenance Medication’ other than an LTRA. |
Kobayashi 31 | 2003 | Case report | 1 | 1 | 17 years | Japanese male | Pranlukast | 450 mg/day | 13 months | Theophylline 400 mg/day. |
Kocyigit 49 | 2013 | Case report | 1 | 1 | 13 years | Male | Montelukast | Not specified | 24–36 hours | Salbutamol, formoterol and budesonide. |
Byrne 50 | 2012 | Case report | 1 | 1 | 9 years | Caucasian male | Montelukast | 5 mg/day | 2.5 years | Beclomethasone inhaler, 50 mcg, 1 puff two times per day. |
Montoro De Francisco 30 | 2015 | Case report | 1 | 1 | 7 years | Male | Montelukast | 4 mg/day | 12 hours | Not specified. |
Scholz 51 | 2019 | Case report | 1 | 1 | 11 years | Male | Montelukast | Not specified | 4 months | Salbutamol and salmeterol/fluticasone. |
Skillman 52 | 2011 | Case report | 2 | 2 |
|
| Montelukast |
|
|
|
Star 53 | 2011 | Case report | 1 | 1 | Teenage | Male | Montelukast | Not specified | Not specified | Escitalopram which was later changed to venlafaxine and risperidone. |
ADR, adverse drug reaction; LTRA, leukotriene receptor antagonist .